Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

v3.10.0.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Jun. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
Number of shares acquired in exchange for common stock   31,745,242   2,090,301  
Precentage of issued and outstanding common stock diluted basis   90.00%      
Common stock issued     38,674,265 38,674,265 35,272,626
Common stock shares outstanding     38,674,265 38,674,265 35,272,626
Accumulated deficit     $ (6,161,956) $ (6,161,956) $ (3,859,086)
Net loss from continuing operations       2,300,000  
Net cash used in operating activities from continuing operations       2,200,000  
Cash and cash equivalents and certificates of deposit       3,300,000  
Certificates of deposit     496,201 $ 496,201
Certificates of deposit maturity date       The certificates of deposit will mature in late September 2018.  
Impairment of long lived assets     $ 0 $ 0  
Subscription Receivable [Member]          
Proceeds from royalty receivable       $ 8,000,000  
CoNCERT Pharmaceuticals, Inc [Member]          
Number of shares acquired in exchange for common stock 2,090,301        
Precentage of issued and outstanding common stock diluted basis 5.93%        
Common stock issued 35,272,626        
Common stock shares outstanding 35,272,626        
Option exercised in exchange for common stock $ 8,000,000        
Percentage of common stock holdings 6.58%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Controlling interest, description Promet’s controlling interest was reduced from 90% to 84%.        
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member]          
Number of shares acquired in exchange for common stock 2,090,301        
Precentage of issued and outstanding common stock diluted basis 5.93%        
Option exercised in exchange for common stock $ 8,000,000        
Percentage of common stock holdings 6.58%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Controlling interest, description Promet’s controlling interest in Processa was reduced from 90% to 84%.        
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member] | Additional Paid-In Capital [Member]          
Proceeds from royalty receivable $ 8,000,000